360° SearchNetwork Hot Spots Trends Time Series

Xiaflex

Type: Product

Name: Xiaflex

First reported May 16 2013 - Updated May 16 2013 - 1 reports

Curved penis treatment promising

When Tony Lee realised that his penis was curving whenever he had an erection - making it painful and difficult for him to have sex - he had no idea what was wrong. He became depressed and very worried, and his relationship with his wife started to c ... [Published Health24 - May 16 2013]

Entities: Xiaflex, Tony Lee, Clinical trials, Collagen

First reported May 15 2013 - Updated May 15 2013 - 1 reports

UBS AG

Auxilium Pharmaceuticals, Inc. To Present At The UBS Global Health Care Conference

CHESTERBROOK, Pa.(Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO )The presentation will also be webcast on the "For Investors" section of the Auxilium website under the "Events" tab on May 21, 2013. To access the live webcast, please log ... [Published Bio-Medicine - May 15 2013]

Entities: Auxilium Pharmaceuticals Inc, Global Health Ltd, UBS AG, Xiaflex

First reported May 10 2013 - Updated May 10 2013 - 5 reports

Phase II

BioSpecifics Technologies' Management Discusses Q1 2013 Results - Earnings Call Transcript

BioSpecifics Technologies Corp. (BSTC) Q1 2013 Earnings Call May 10, 2013 8:30 AM ETOperatorThank you for holding. Welcome to the BioSpecifics’ Q1 2013 Financial Results Conference Call. (Operator instructions.) I would like to introduce your host for ... [Published Seeking Alpha - May 10 2013]

Entities: Xiaflex, BioSpecifics Technologies Corp, Dupuytren's contracture, Phase II

First reported May 10 2013 - Updated May 10 2013 - 1 reports

Auxilium Pharmaceuticals, Inc. To Present At The Bank Of America Merrill Lynch 2013 Health Care Conference

CHESTERBROOK, Pa.The presentation will also be webcast on the "For Investors" section of the Auxilium website under the "Events" tab on May 15, 2013. To access the live webcast, please log on to Auxilium's website approximately fifteen minutes prior to ... [Published Bio-Medicine - May 10 2013]

Entities: Auxilium Pharmaceuticals Inc, Bank of America Merrill Lynch, Xiaflex, Health Care

First reported May 10 2013 - Updated May 10 2013 - 2 reports

BioSpecifics Technologies Corporation Reports First Quarter 2013 Financial Results

/PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX(R) in the U.S., announced today that it will host a conference call and live audio webcast ... [Published BioSpace - May 10 2013]

Entities: BioSpecifics Technologies Corp, Xiaflex, United States

First reported May 08 2013 - Updated May 08 2013 - 1 reports

Auxilium Pharmaceuticals Inc

Auxilium Pharmaceuticals Q1 net loss widens

Auxilium Pharmaceuticals, Inc., a biopharmaceutical company, has reported that net loss for the first quarter ended March 31, 2013 was $8.16 million, or $0.17 loss per share, compared to a net loss of $1.75 million, or $0.04 loss per share, for the same ... [Published Individual.com - May 08 2013]

Entities: Auxilium Pharmaceuticals Inc, Adrian Adams, Xiaflex

First reported May 08 2013 - Updated May 08 2013 - 3 reports

Treatment for Painful Curved Penis Shows Promise

Font SizeAAA Xiaflex up for FDA approval later this year, but some experts think injections required would be a hard sellWebMD News from HealthDayBy Barbara Bronson GrayHealthDay ReporterWEDNESDAY, May 8 (HealthDay News) -- Some diseases are especially ... [Published WebMD - May 08 2013]

Entities: Tony Lee, Penis, Verapamil, Xiaflex

First reported May 03 2013 - Updated May 03 2013 - 3 reports

BioSpecifics Technologies Corp. to Host Conference Call to Report First Quarter 2013 Financial Results on Friday, May 10, 2013

LYNBROOK, N.Y.In order to participate in the conference call, please dial 1-800-860-2442 (domestic) or 1-412-858-4600 (international). The live webcast can be accessed under "Calendar of Events" in the Investor Relations section of the Company's website ... [Published Bio-Medicine - May 03 2013]

Entities: BioSpecifics Technologies Corp, Dupuytren's contracture, collagenase

First reported May 02 2013 - Updated May 02 2013 - 1 reports

Aetna Inc. (AET), Auxilium Pharmaceuticals, Inc. (AUXL), and ArthroCare Corporation (ARTC): 3 Healthcare Stocks to Avoid

Insiders have information about a company which is not available to outside investors. On the other hand, institutional investors have a lot of resources at their disposal to better assess a stock, something which is not possible for retail investors. ... [Published InsiderMonkey.com - May 02 2013]

Entities: Auxilium Pharmaceuticals Inc, Aetna Inc, Arthrocare Corporation

First reported May 01 2013 - Updated May 01 2013 - 1 reports

Auxilium Pharma Receives “Neutral” Rating from Zacks (AUXL)

Auxilium Pharma (NASDAQ: AUXL)Zacks' analyst wrote, "Auxilium's first quarter results were disappointing with the company reporting a loss of $0.12 per share, wider than the year-ago loss of 4 cents and the Zacks Consensus Estimate of earnings of 7 cents. ... [Published American Banking News - May 01 2013]

Entities: Auxilium Pharmaceuticals Inc, Xiaflex, Earnings Per Share, Canaccord Genuity Corp, RBC Capital Markets

First reported Apr 30 2013 - Updated May 01 2013 - 3 reports

Auxilium Pharmaceuticals, Inc. (AUXL), AbbVie Inc (ABBV), Eli Lilly & Co. (LLY): Is The Risk Worth The Large Potential Reward?

Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL ) stock has a lot of negative sentiment priced into the shares, maybe too much at this point. Often when the Street has bearish outlook on a stock, interest in it falls off and the shares overshoot fair value. ... [Published InsiderMonkey.com - May 01 2013]

Entities: Auxilium Pharmaceuticals Inc, ABBVIE INC., Eli Lilly & Company, Xiaflex, Upsher-Smith Laboratories, Inc.

First reported Apr 29 2013 - Updated Apr 30 2013 - 11 reports

Auxilium Snaps Up Urolology Therapeutics Firm Actient in $585M Deal

Auxilium Pharmaceuticals is slated to acquire urology therapeutics firm Actient Holdings in a $585 million up-front cash deal. Through this acquisition, Auxilium also expects to receive a tax benefit with a net value of around $60 million, at present ... [Published Genetic Engineering News - Apr 29 2013]

Entities: Therapeutics, Adrian Adams, Xiaflex, Auxilium Pharmaceuticals Inc

Quotes

"For a man to dread sex, it's just not natural," he said. "There were times when I would stay up late on purpose, just to make sure my wife was sleeping before I got into bed. I was just totally embarrassed."

Curved penis treatment promising [Published Health24 - May 16 2013]

"To have our work recognized by the Graphic Arts Association is truly an honor," Innovative President Rob Whitman said. "These awards are a testament to the creativity of our team and to our high quality printing solutions. All of these required collaboration by customer, designer, and printer to deliver such excellence!"

Innovative Print and Media Group Wins Seven More Awards in Neographics Competition [Published 1888PressRelease - May 11 2013]

"We are very pleased to have completed enrollment in our Phase II trials in canine and human lipoma and we remain on track to report top-line data for both trials in the second half of this year" reflected Thomas L Wegman, President of BioSpecifics. $ First Quarter 2013 Financial Results

BioSpecifics Technologies Corp. Reports First Quarter 2013 Financial Results PR Newswire [Published Yahoo! Finance - May 10 2013]

...we remain on track to report top-line data for both trials in the second half of this year," reflected Thomas L Wegman, President of BioSpecifics. "In addition, there are a number of exciting upcoming milestones for XIAFLEX this year. We are looking forward to the potential approval of XIAFLEX for the treatment of Peyronie's Disease in the third quarter of this year and if approved, we would anticipate the U S commercial launch in this indication in the fourth quarter of 2013. We are also eagerly awaiting the initiation of a new clinical trial for XIAFLEX in frozen shoulder syndrome in the second half of this year, following the announcement of the statistically significant top-line data from the Phase IIa study, as well as the initiation of a Phase II study in the cellulite indication during the same time period. Finally we believe there is tremendous potential for XIAFLEX in the treatment of many medical conditions caused by excess collagen accumulation and BioSpecifics will continue to devote its efforts to the development in new clinical indications in the future."

BioSpecifics Technologies Corp. Reports First Quarter 2013 Financial Results [Published NewsBlaze - May 10 2013]

More Content

sort by: Date \| Relevance
Curved penis treatment promising [Published Health24 - May 16 2013]
Auxilium Pharmaceuticals, Inc. To Present At Th... [Published Bio-Medicine - May 15 2013]
Innovative Print and Media Group Wins Seven Mor... [Published 1888PressRelease - May 11 2013]
Innovative Print & Media Group Wins Seven More ... [Published PR Urgent - May 11 2013]
BioSpecifics Technologies' Management Discusses... [Published Seeking Alpha - May 10 2013]
Auxilium Pharmaceuticals, Inc. To Present At Th... [Published Bio-Medicine - May 10 2013]
Auxilium Pharmaceuticals, Inc. To Present At Th... [Published PR Newswire - May 10 2013]
BioSpecifics Technologies Corporation Reports F... [Published BioSpace - May 10 2013]
BioSpecifics Technologies Corporation (BSTC) Re... [Published BioSpace - May 10 2013]
BioSpecifics Technologies Corp. Reports First Q... [Published Yahoo! Finance - May 10 2013]
BioSpecifics Technologies Corp. Reports First Q... [Published NewsBlaze - May 10 2013]
BioSpecifics Technologies Corp. Reports First Q... [Published ADVFN UK - May 10 2013]
BioSpecifics Technologies Corp. Reports First Q... [Published Staten Island Live - May 10 2013]
BioSpecifics Technologies Corp. Reports First Q... [Published PR Newswire: Financial Services - May 10 2013]
Tesoro Corporation (TSO), Krispy Kreme Doughtnu... [Published InsiderMonkey.com - May 08 2013]
Auxilium Pharmaceuticals Q1 net loss widens [Published Individual.com - May 08 2013]
High Response to Enzyme in Peyronie's [Published MedPage Today - May 08 2013]
Treatment for Painful Curved Penis Shows Promise [Published WebMD - May 08 2013]
Treatment for Painful Curved Penis Shows Promise [Published WebMD - May 08 2013]
Treatment for Painful Curved Penis Shows Promise [Published Health Finder - May 08 2013]
Deals of the Week Looks at Ultra-Orphan Drug Pr... [Published The IN VIVO Blog - May 05 2013]
BioSpecifics Technologies Corp. to Host Confere... [Published Bio-Medicine - May 03 2013]
BioSpecifics Technologies Corp. to Host Confere... [Published FinanzNachrichten.de - May 03 2013]
BioSpecifics Technologies Corp. to Host Confere... [Published WTNZ - May 03 2013]
BioSpecifics Technologies Corp. to Host Confere... [Published PR Newswire: Health - May 03 2013]
Aetna Inc. (AET), Auxilium Pharmaceuticals, Inc... [Published InsiderMonkey.com - May 02 2013]
3 Healthcare Stocks to Avoid [Published Motley Fool - May 02 2013]
Auxilium Pharma Receives “Neutral” Rating from ... [Published American Banking News - May 01 2013]
Auxilium Pharmaceuticals, Inc. (AUXL), AbbVie I... [Published InsiderMonkey.com - May 01 2013]
Weak Quarter At Auxilium Overshadows Execution ... [Published Seeking Alpha - May 01 2013]

Blogs

sort by: Date \| Relevance
Deals of the Week Looks at Ultra-Orphan Drug Pr... [Published The IN VIVO Blog - May 05 2013] In the first half of 2013, two drugs will have launched in the US priced at $250,000 per patient annually: Both address serious, ultra-rare diseases and are backed by KOLs and patients. But the similarities stop there. Three months into its launch, ...
Auxilium Pharmaceuticals Earnings: Here’s Why t... [Published Wall St. Cheat Sheet - Apr 29 2013] Auxilium Pharmaceuticals Inc. ( NASDAQ:AUXL ) had a loss and missed Wall Street’s expectations, AND came up short on beating the revenue expectation. The revenue miss is a negative sign to shareholders seeking high growth out of the company. Shares are ...
Auxilium Pharmaceuticals Earnings: Here’s Why t... [Published Wall St. Cheat Sheet - Apr 29 2013] Auxilium Pharmaceuticals Inc. ( NASDAQ:AUXL ) had a loss and missed Wall Street’s expectations, AND came up short on beating the revenue expectation. The revenue miss is a negative sign to shareholders seeking high growth out of the company. Shares ...
Auxilium reports positive data from Phase IIa f... [Published PBR - News - Mar 26 2013] Specialty biopharmaceutical company Auxilium Pharmaceuticals has reported positive top-line results from Xiaflex (collagenase clostridium histolyticum or CCH) frozen shoulder syndrome Phase IIa study. ...
Human medicines European Public Assessment Repo... [Published Pending EC decisions and European Public Assess ... - Feb 28 2013]

Press Releases

sort by: Date \| Relevance
Auxilium Pharmaceuticals, Inc. To Present At Th... [Published PR Newswire - May 10 2013]
BioSpecifics Technologies Corp. Reports First Q... [Published PR Newswire: Financial Services - May 10 2013]
BioSpecifics Technologies Corp. to Host Confere... [Published PR Newswire: Health - May 03 2013]
BioSpecifics Technologies Corp. Announces Posit... [Published PR Newswire - Mar 26 2013]
BioSpecifics Technologies Corp. Announces Posit... [Published PR Newswire: Health - Mar 26 2013]